Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor of the calcitonin secreting thyroid C-cells. Somatic and germline mutations in the RET proto-oncogene are associated with sporadic and inherited cases of MTC, respectively. The human MTC cell line, TT, can be dierentiated by activated raf-1. This dierentiation is characterized, in part, by down-regulation of the RET proto-oncogene. We now show that raf-1 induction is followed by activation of the downstream kinases MEK1/2 and ERK1/2 and that dierentiation is dependent on activation of MEK1/2. The concurrent down-regulation of RET appears to involve altered nuclear compartmentalization and transport of RET mRNA. Although RET is down-regulated during raf-1 mediated dierentiation, overexpression of activated RET alleles which resist down-regulation does not alter the raf-1 mediated dierentiation response. These data suggest that RET down-regulation is associated with, but not required, for raf-1 mediated MTC cell dierentiation and that the raf-1 signal transduction pathway plays a dominant role in promoting MTC cell dierentiation.
Introduction
Medullary thyroid carcinoma (MTC) is an endocrine tumor of the calcitonin (CT) producing parafollicular C-cells of the thyroid (Hazard et al., 1959) which can arise sporadically, or as part of three distinct hereditary endocrinopathies. Activating mutations in the RET protooncogene have been described in all forms of MTC. RET is a receptor tyrosine kinase (Takahashi and Cooper, 1987) which interacts with glial cell linederived neurotrophic factor (GDNF) (Durbec et al., 1996; Jing et al., 1996; Treanor et al., 1996; Trupp et al., 1996) and a newly described, related protein, neurturin (NTN) (Buj-Bello et al., 1997; Creedon et al., 1997; Klein et al., 1997) , via coreceptors GDNFR-a and NTNR-a respectively. Commonly, mutations in extracellular cysteine residues encoded by exons 10 and 11 of RET are associated with two inherited MTC syndromes, familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia type 2A (MEN 2A) (Donis-Keller et al., 1993; Mulligan et al., 1993) . The predominant mutation in MEN 2B, a hereditary MTC syndrome more aggressive than MEN 2A, and in sporadic MTC, is a single missense mutation in exon 16 resulting in the replacement of a methionine with a threonine at codon 918 in the tyrosine kinase domain (Carlson et al., 1994; Eng et al., 1994; Hofstra et al., 1994.) . These changes in the RET gene have been shown to be activating mutations leading to inappropriate kinase activity (Pasini et al., 1997) . Thus, unlike most hereditary cancer syndromes in which causative germ-line mutations reside in tumor suppressor genes, hereditary MTC is caused by events which render the RET gene oncogenic. This constitutive activation of the RET tyrosine kinase presumably provides the initial growth stimulus leading to development of MTC. Thus, it becomes critical to understand the role of RET in the development and/or progression of this tumor.
To examine the interaction of RET and the MTC cell phenotype, we have exploited the TT cell line of human MTC. We previously demonstrated that introduction of a v-Ha-ras oncogene into this cell line resulted in dierentiation of the cells (Nakagawa et al., 1987) . We have further demonstrated that activation of a stably expressed raf-1:estrogen receptor fusion construct (DRaf-1:ER) (Samuels et al., 1993) recapitulates the TT cell dierentiation achieved with v-Ha-ras (Carson et al., 1995) and that DRaf-1:ER mediated TT differentiation results in down-regulation of RET expression at both the mRNA and protein levels (Carson et al., 1995) . This ®nding has allowed us to examine how ras/raf signal transduction may mediate RET down-regulation and, importantly, whether down-regulation of RET gene expression is required to permit dierentiation of MTC cells. We now show that activation of DRaf-1:ER results in activation of MEK1/2 and the MAP kinases, ERK1/2 (extracellular signal regulated kinase) leading to TT cell dierentiation. We also demonstrate that RET silencing during dierentiation is not due to a transcriptional block, but may be due to impaired nuclear export of the mRNA. Finally, we demonstrate that RET downregulation is not required for dierentiation to occur, indicating that the raf-1 pathway is dominant to the RET signal in established MTC cells.
Results

DRaf-1:ER signal transduction
In order to further characterize raf-1 signal transduction in MTC cells, we examined activation of downstream targets of raf-1 signaling. In the`classic' ras/raf/ MEK/MAPK pathway, activated raf phosphorylates and activates MEK1/2 which, in turn, phosphorylates and activates ERK1/2 (Marshall, 1995) . TT:DRaf-1:ER cells are a human MTC cell line expressing a raf-1:estrogen receptor fusion protein, in which the raf-1 kinase can be activated by treatment with b-estradiol (Carson et al., 1995) . These TT:DRaf-1:ER cells were treated with 1 mM b-estradiol for 48 h to activate the raf-1 kinase and dierentiate the cells. Control cells were treated with ethanol, the carrier for the bestradiol. Activation of MEK1/2 was measured by Western analysis and an in vitro kinase assay. MEK1/2 is activated by phosphorylation of two serine residues within kinase subdomain VIII (Alessi et al, 1994; Zheng and Guan, 1994 ). An antibody speci®c for the phosphoserine form of MEK1/2 demonstrated high levels of activated MEK1/2 in b-estradiol dierentiated TT:DRaf-1:ER cells compared to very low levels of MEK1/2 activity in control cells (Figure 1a) . bestradiol treatment of parental TT cells which did not express DRaf-1:ER had no eect on MEK1/2 phosphorylation (data not shown). This result indicates that activation of DRaf-1:ER induces phosphorylation of MEK1/2.
Coupled in vitro kinase assays (Alessi et al., 1994) were performed in order to con®rm that phosphorylation of MEK1/2 correlated with activation of the kinase properties of these proteins. Protein lysates were collected from TT:DRaf-1:ER cells treated for 48 h with b-estradiol or ethanol. MEK1 and MEK2 were immunoprecipitated from the lysates with isoformspeci®c monoclonal antibodies. Immunoprecipitated MEK was used to phosphorylate an inactive GST-MAPK fusion protein, which, thus activated, was able to phosphorylate myelin basic protein (MBP). After 48 h in b-estradiol to induce raf-1, there was an increase in phosphorylation of MBP due to both MEK1 and MEK2 kinase activites (Figure 1b ). These data con®rm that the phosphorylation of MEK1/2 correlates with kinase activity.
In order to determine whether activation of MEK1/2 was required for TT:DRaf-1:ER dierentiation or whether DRaf-1:ER activity could trigger differentiation independent of MEK1/2, perhaps through cross talk with a parallel signal transduction pathway, we dierentiated the cells in the presence of the MEK inhibitor, PD098059 (Alessi et al., 1995; Dudley et al., 1995) . PD098059 prevents the activation of MEK1, and to a lesser extent activation of MEK2, by activated raf. Pretreatment with PD098059, followed by addition of b-estradiol, prevented the morphological changes associated with dierentiation, and cell growth was not arrested. Treatment with 10 ± 50 mM PD098059 inhibited activation of MEK1/2 in TT:DRaf-1:ER cells, as measured by a decrease in the ability of immunoprecipitated MEK1 and MEK2 to generate phosphorylated MBP in a coupled in vitro kinase assay ( Figure  1b) . Thus, DRaf-1:ER mediated TT cell dierentiation requires activation of MEK1/2.
Activation of the downstream MAPK proteins ERK1 and ERK2 during TT:DRaf-1:ER cell differentiation was measured by examination of MAPK phosphorylation levels, and by enzymatic assay. TT:DRaf-1:ER cells were dierentiated for 48 h with b-estradiol, and the cells were harvested for Western blots or in vitro kinase assays. Antibodies speci®c for active ERK1/2, phosphorylated on both threonine and tyrosine within a Thr-X-Tyr consensus sequence, demonstrated an increase in phosphorylated ERK1/2 after a 48 h treatment with b-estradiol to induce DRaf-1:ER (Figure 2a ). ERK2 immunoprecipitated from MTC cells dierentiated by activation of the DRaf-1:ER construct showed increased activity, as measured by phosphorylation of MBP (Figure 2b) . b-estradiol treatment of parental TT cells had no eect on ERK1/ 2 activity (data not shown).
We also measured inhibition of ERK1/2 activity after PD098059 treatment followed by addition of bestradiol. In vitro kinase assays con®rmed that ERK1/2 activity was inhibited by pretreatment with PD098059, although phosphorylation of MBP was still above control levels (Figure 2b ). These data suggest that PD098059 prevents the full activation of ERK1/2 required for TT:DRaf-1:ER dierentiation.
Previous work had demonstrated an increase in c-jun mRNA and AP-1 protein activity during v-Ha-ras mediated TT cell dierentiation (Nelkin et al., 1990) . A similar increase in c-jun mRNA, which is a key protein in the JNK/SAPK pathway, occurs during DRaf-1:ER mediated TT cell dierentiation (data not shown). However, no increase in c-jun protein levels or phosphorylation of c-jun could be detected (data not shown), suggesting that MEK1/2 and ERK1/2 are the major eectors of raf-1 kinase activity controlling TT:DRaf-1:ER dierentiation and that the JNK/SAPK pathway is a minor contributor, if at all.
Mechanism of RET silencing during MTC dierentiation
We have previously demonstrated that raf-1 induced dierentiation of the TT:DRaf-1:ER cells silences RET mRNA expression (Carson et al., 1995) . In order to understand how the raf-1/MEK/ERK signaling pathway induced down-regulation of RET, we performed nuclear run-o assays to determine whether RET was transcriptionally silenced. TT:DRaf-1:ER cells were treated with ethanol or b-estradiol for 48 h and the nuclei were harvested for run-o analysis. Northern blots of poly (A) + mRNA have shown that steady state RET expression is silenced after 48 h of dierentiation. However, nuclear run-os showed no dierence in RET transcription in control or b-estradiol treated nuclear preparations (Figure 3a) . Thus, the downregulation of RET expression is not explained by transcriptional repression.
In order to test whether RET silencing could be due to transcription initiation followed by an RNA elongation block, the cDNA probe was divided into 5', middle, and 3' probes of similar lengths which were immobilized and used in run-o assays. Equivalent signals for all three probes were detected in run-o RNA from cells cultured for 48 h in the presence of either ethanol carrier or b-estradiol, indicating that a RET elongation block does not occur during TT:DRaf-1:ER dierentiation (Figure 3b ).
We next asked whether a decrease in the half-life of RET mRNA was responsible for the down-regulation of expression. TT:DRaf-1:ER cells were pretreated with b-estradiol to initiate the dierentiation process. The cells were then treated with actinomycin D to block new RNA synthesis and total RNA was harvested from the cells at several time points. RNase protection analyses were used to quantitate the level of RET mRNA present in the control and dierentiated samples and compare the decay rate of the messages.
These experiments showed no dierence in the decay rate of RET mRNA (Figure 4 ). RET mRNA from both the control and the b-estradiol treated cells had a half-life of greater than 12 h, as previously reported for RET mRNA (Tahira et al., 1991) . However, it was repeatedly seen that the level of b-estradiol treated RET mRNA was already reduced by the time the actinomycin D was added (generally about 16 h after addition of the ethanol or b-estradiol). These results demonstrate that the steady-state level of RET mRNA declines during dierentiation, but no change in RET mRNA half-life was detected.
We tested whether the loss of RET message could be due to a failure of the mRNA to exit the nucleus. Nuclear and cytoplasmic RNA fractions were isolated from TT:DRaf-1:ER cells treated with ethanol or bestradiol. RNase protection assays were used to quantitate the levels of RET message. After 48 h of dierentiation, RET message, although decreased, could repeatedly be detected in the nuclear RNA fraction ( Figure 5a ). No evidence for smaller, alternatively processed nuclear RNA species was detected. Comparison of cytoplasmic and nuclear RNAs showed an initial increase in nuclear RET mRNA was followed by a decrease in the levels of nuclear RET message, during the time that a steady decline was occurring in cytoplasmic RET mRNA ( Figure 5b ). These dynamics suggest that nuclear retention of the RET transcript, followed by loss of the retained RET mRNA, may contribute to the steady-state down-regulation of RET.
RET overexpression in TT:DRaf-1:ER cells
Since activating mutations in RET are believed to contribute to overproliferation of C-cells and lead to eventual MTC, we reasoned that the dierentiation and growth cessation of TT cells following activation of DRaf-1:ER construct may depend on the silencing of the RET gene. To address this issue, we asked whether overexpression of an exogenous, activated RET gene that resisted down-regulation during activation of the raf-1 pathway, could alter the dierentiation response. Retroviral constructs containing either a MEN 2A (Cys634Arg) or MEN 2B (Met918Thr) mutation and referred to as RET2A and RET2B, respectively, were packaged and initially tested for function by infecting NIH3T3 cells and PC12 cells. The activated RET constructs, but not the vector, pBabehygro, generated foci in NIH3T3 cells and caused neurite-like extensions in PC12 cells (data not shown). These results are identical to others (Asai et al., 1995; Califano et al., 1995; Santoro et al., 1995) Figure 5 (a) RNase protection analysis of cytoplasmic vs nuclear RET mRNA. The colon cancer cell line, RKO, serves as a negative control for RET mRNA. Cells were harvested at indicated times after addition of b-estradiol. Bands were quantitated by PhosphorImager analysis. (b) Relative RET mRNA levels, corrected for RNA loading, with 0 h set as 100%. Cytoplasmic RET (C) shows the previously demonstrated down-regulation. Nuclear RET (N) shows accumulation followed by a decrease Figure 4 Half-life of RET mRNA during dierentiation of TT:DRaf-1:ER cells. Cells were treated with b-estradiol (E2) or ethanol (C) for 16 h. Actinomycin D was then added. Cells were harvested at the indicated time points and RET mRNA levels were analysed by RNase protection assay. No substantial dierence in decay of RET mRNA was detected. However, the overall level of RET mRNA in the E2 samples was repeatedly 50 ± 60% of the C level. One representative experiment is shown Immunoblots were developed with anti-phosphotyrosine antibody. Hygro represents a vector only negative control cell line. 2A is a pooled population expressing RET2A (RET Cys634Arg). 2B4.1 and 2B5.2 are clones expressing RET2B (RET Met918Thr). (b) Competitive RT ± PCR for RET2A expression. Exogenous RET is present in the lower band after restriction digest. Lanes 1, 2 and 3 represent control reaction to judge ratios of endogenous versus exogenous product. Lane 1, 10 : 1 ratio of wt RET vs RET2A. Lane 2, 1 : 1 ratio of wt RET vs RET2A. Lane 3, 1 : 10 ratio of wt RET vs RET2A. (c) Competitive RT ± PCR for RET2B expression. Exogenous RET is present in the lower band after restriction digest. Lanes 1, 2 and 3 represent control reactions to judge ratios of endogenous versus exogenous product. Lane 1, 10 : 1 ratio of RET2B vs wt RET. Lane 2, 1 : 1 ratio of RET2B vs wt RET. Lane 3, 1 : 10 ratio of RET2B vs wt RET and con®rmed that the RET proteins expressed by the RET2A and RET2B constructs were functional. These RET2A, RET2B, and vector producer lines were used to infect TT:DRaf-1:ER cells. Stable pooled and clonal populations were selected, and the RET2A and RET2B overexpressing cells were shown to continue to express tyrosine phosphorylated RET protein after b-estradiol treatment (Figure 6a ). This represented activated, exogenous RET protein, since DRaf-1:ER induced dierentiation silences the endogenous RET. This result suggests that sequences present in the 5' and 3' non-coding domains of RET, but absent in the constructs, may contribute to normal mRNA down-regulation and RET silencing. To further con®rm that we were detecting exogenous RET after bestradiol treatment, RNA was harvested from control and b-estradiol treated populations and a competitive RT ± PCR, followed by restriction digest to selectively cut the exogenous allele (Marsh et al., 1996) , was used to compare the ratio of endogenous and exogenous RET mRNA. After 48 h of b-estradiol treatment, the ratio of exogenous to endogenous RET transcripts increased (Figure 6b ). These experiments con®rmed that the endogenous steady state RET message was down-regulated, but that the exogenous RET mRNA continued to be expressed.
TT:DRaf-1:ER RET overexpressing cells showed no morphological dierences from the parental or vector only populations and all grew at comparable rates, doubling approximately every 83 h. After 48 h in bestradiol, TT:DRaf-1:ER RET2A and RET2B cells rounded up in the same manner as the parental and vector only TT:DRaf-1:ER cells (Figure 7 ). Growth curves showed that, like the parental TT:DRaf-1:ER cells, the cells overexpressing exogenous RET2A or RET2B ceased proliferating after the addition of bestradiol activation of raf-1 kinase (Figure 8a) . Thus, it appears that silencing of RET is not required for the morphological and proliferative changes associated with TT:DRaf-1:ER dierentiation. The calcitonin gene transcript is alternatively spliced to produce CT, an endocrine marker, and CGRP, a neural marker. A high CT/CGRP mRNA ratio is associated with an endocrine phenotype and is a hallmark of TT:DRaf-1:ER dierentiation. We harvested RNA from the TT:DRaf-1:ER RET2A and RET2B cells during b-estradiol triggered dierentiation and quantitated the levels of CT and CGRP by Northern blot, using probes speci®c for CT or CGRP. RET2A and RET2B overexpressing cells demonstrated a 5 ± 7-fold increase in the CT/CGRP mRNA ratio over 72 h of dierentiation, identical to the control cell line (Figure 8b) . Thus, the collective evidence demonstrates that RET silencing is associated with, but is not required, for DRaf-1:ER mediated TT cell dierentiation.
When the b-estradiol is removed from TT:DRaf-1:ER cells after 48 h, the dierentiated cells remain viable for long periods of time but fail to proliferate. This suggests that DRaf-1:ER mediated MTC cell dierentiation is terminal. We considered the possibility that although the RET2A and RET2B overexpressors dierentiated after b-estradiol administration, this dierentiation might no longer be terminal. To address this, the RET overexpressing and control TT:DRaf-1:ER cells were dierentiated in b-estradiol for 48 h and then the estradiol or ethanol containing media were replaced with regular media. No reversion to¯at morphology or return to proliferation was detected in the cell lines tested (data not shown), suggesting that dierentiation is terminal despite continued RET expression.
Discussion
As a neuroendocrine tumor derived from neural crest cells, cultured MTC cells provide a model system for the study of neuroendocrine dierentiation. The human MTC cell line, TT, dierentiates in the presence of activated v-Ha-ras or an activated raf-1 construct (Carson et al., 1995; Nakagawa et al., 1987) . In order to de®ne the targets of DRaf-1:ER activation in TT cells, we initially chose to examine the phosphorylation and activation of members of the`classic' ras/raf pathway. We demonstrate that b-estradiol induced dierentiation of TT:DRaf-1:ER cells is correlated with phosphorylation and activation of MEK1/2 and ERK1/2 downstream of raf-1. When the MEK inhibitor PD098059 is added to the cells before bestradiol, TT:DRaf-1:ER dierentiation is blocked. The inhibition of dierentiation is due to the prevention of MEK activation, as measured by an in vitro kinase assay, con®rming that raf-1 acts through MEK1/2 and ERK1/2 during TT:DRaf-1:ER cell dierentiation. Furthermore, although past work has demonstrated an increase in c-jun RNA during v-Ha-ras differentiation of TT cells, we were unable to document any change in the JNK/SAPK pathway during raf-1 mediated TT cell dierentiation.
It was noted that even though treatment with PD098059 prevented raf-induced dierentiation, the drug did not completely abrogate ERK1/2 activity, although it did substantially diminish it. These results suggest that low level ERK1/2 activity is insucient to promote TT:DRaf-1:ER dierentiation. Studies by several groups have demonstrated that dosage and duration of MAPK activity can determine the outcome of the signal (Marshall, 1995 , while low level activity has a mitogenic eect (Sewing et al., 1997; Woods et al., 1997) . These studies are consistent with the observation that moderate ERK1/2 activity is insucient to reach the threshold required to dierentiate TT:DRaf-1:ER cells. It is also possible that some of the eects of MEK in TT cell dierentiation are not mediated through MAPK; such MAPK-independent eects have been seen in other systems (D'Arcangelo and Halegoua, 1993; Holt et al., 1996) . Whether inducible MEK or MAPK constructs can individually trigger TT cell dierentiation or whether additional signaling components are required will need to be addressed in subsequent investigations.
TT cell harbor a MEN 2A-like RET mutation (Cys634Trp) and constitutively express active RET protein . Hence, potentially proliferative RET signals from the activated RET gene are silenced along with wild-type RET during raf-1-induced growth arrest and dierentiation of TT cells. It was therefore of interest to determine whether the loss of active RET expression was necessary for dierentiation. We have shown that raf-1 is still able to induce dierentiation in the presence of activated exogenous RET, the expression of which is not silenced. This ability of raf-1 to induce dierentiation in the presence of activated RET suggests that while mutant RET signaling may be critical, in genetic forms of MTC, for the initial expansion of hyperplastic Ccells, activated exogenous RET, alone, may not ensure continued proliferation of established MTC cells. The signal transduction cascade initiated by activation of raf-1 appears to be dominant over the signal generated by continued expression of a mutated RET gene. Alternatively, fully established MTC cells may become indierent to RET kinase activity due to loss of speci®c downstream targets or the acquisition of additional, dominant genetic mutations. In this setting, the cells might be insensitive to overexpressed RET and respond to the activated raf-1 construct. It is also possible that the dose of MAPK activity generated by the mutant RET kinase might be sucient to elicit inappropriate proliferation (leading to C-cell hyperplasia and/or MTC), but not high enough to trigger terminal dierentiation, unlike the MAPK activity generated by DRaf-1:ER. Other groups have demonstrated that low level raf-1 activity, such as might be caused by activated RET, is mitogenic, while high level raf-1 activity, like that caused by DRaf-1:ER induction, induces growth arrest (Sewing et al., 1997; Woods, et al., 1997) . An additional possibility is that the DRaf-1:ER construct and/or mutant RET protein target not just MEK and MAPK, but additional dierentiation or proliferation speci®c substrates, respectively, as has been suggested by Kuo et al. (1996 Kuo et al. ( , 1997 . In fact, it may prove that a combination of dosage eects and speci®c target genes work in conjunction to generate a tailored response to environmental signals.
We now show that RET silencing following raf-1 activation is not due to inhibition of transcription or a block in mRNA elongation. Nor did we ®nd evidence for a decrease in RET mRNA half-life during dierentiation. However, we cannot rule out the possibility that addition of actinomycin D may interfere with the dierentiation process and inhibit an active RNA degradation process, thereby masking a decrease in RET mRNA half-life. The mechanism for RET down-regulation during raf-1 induced differentiation appears to be associated with some aspect of nuclear processing of RET gene mRNA. Residual nuclear RET mRNA was present 48 hours after addition of b-estradiol and at a time where little or no cytoplasmic RET mRNA could be detected. This ®nding suggests that nuclear retention of the processed RET message, followed by nuclear RNA degradation, may contribute to the dramatic loss of steady state RET mRNA following DRaf-1:ER activation. Pulsechase experiments revealed no change in RET protein half-life during dierentiation (data not shown), suggesting that regulation of the RET mRNA is primarily responsible for RET silencing.
The molecular steps underlying raf-1-induced alterations in RET mRNA processing in the nucleus are not yet clear. RET is transcribed at low levels in TT cells. RET mRNA may be transcribed and processed in the nucleus, where, if not promptly exported to the cytoplasm, it is rapidly degraded. Once in the cytoplasm, the RET mRNA transcript may be stabilized to compensate for low transcriptional levels. Nuclear retention of newly transcribed RET message would result in rapid turnover of the trapped mRNA while the remaining cytoplasmic RET mRNA would undergo normal degradation characterized by a 412 h half-life, as is supported by our data.
In summary, we have demonstrated that raf-1 works through MEK and ERK in the dierentiation pathway of TT DRaf-1:ER cells. While this dierentiation is associated with silencing of the RET proto-oncogene, such down-regulation is not required for dierentiation to proceed in our experimental model. Nevertheless, our demonstrated relationship between the MAPK signal transduction pathway and RET silencing highlights a signal transduction cascade which may, in part, trigger altered gene expression through a block in nuclear export of mRNA transcripts. These results indicate that multiple levels of regulation for growthrelated genes, in addition to more traditional levels of transcriptional and post-transcriptional control, may be operative in regulation of cell growth and dierentiation. Continued studies of the MTC culture model should allow further dissection of the signal transduction mechanisms which regulate neuroendocrine cell dierentiation.
Materials and methods
Reagents
Chemicals, unless otherwise speci®ed, were from Sigma. Anti-phospho MEK1/2 polyclonal antibody and control anti-MAPK antibody were from New England Biolabs.
Anti-MEK1 and anti-MEK2 monoclonal antibodies were from Transduction Laboratories. Anti-active MAPK polyclonal antibody was from Promega. Anti-ERK1 and anti-ERK2 polyclonal antibodies, anti-RET polyclonal antibody (#sc-167), goat anti-rabbit and goat anti-mouse antibodies were from Santa Cruz Biotechnology. Antiphosphotyrosine antibody 4G10 was from Upstate Biotechnology, Inc.
Cell culture
Generation of the TT DRaf-1:ER line and its maintenance have been previously described (Carson et al., 1995) . RET overexpressing TT DRaf-1:ER cells were maintained in phenol-red free RPMI (Gibco ± BRL Life Technologies) supplemented with 16% fetal bovine serum, 100 U/ml penicillin/streptomycin (Paragon), 0.25 mg/ml geneticin (Calbiochem) plus 0.2 mg/ml hygromycin (Calbiochem). NIH3T3 cells were grown in DMEM (Paragon) supplemented with 10% bovine calf serum (Paragon) and 100 U/ ml penicillin/streptomycin. PC12 cells were grown in DMEM supplemented with 10% horse serum, 5% fetal bovine serum, and 100 U/ml penicillin/streptomycin. PA317 cells were maintained in DMEM media plus 10% fetal bovine serum and 100 U/ml penicillin/streptomycin. Cells were maintained at 378C with 5% CO 2 . TT:DRaf-1:ER cells were dierentiated by the addition of 1 mM bestradiol to the media for 48 h. An equivalent dilution of ethanol, the carrier for the b-estradiol, was used to treat control cells.
Western analysis
Cells were trypsinized and pellets of 10 6 cells were dissolved in 26Laemmli buer (0.125 M Tris, 20% glycerol, 4% SDS, 10% b-mercaptoethanol, 0.006% bromophenol blue). Cell pellets were boiled 5 min and electrophoresed through 15% SDS-polyacrylamide gels. Gels were transferred to Immobilon-P membrane (Millipore). Membranes were blocked for at least two hours in 5% BSA in TTBS (0.1 M Tris, 150 mM NaCl, 0.1% Tween-20). Filters were incubated for 2 h at 258C with a 1 : 1000 dilution of antiphospho-MEK1/2 or a 1 : 20 000 dilution of anti-active-MAPK in 5% BSA/TTBS. Filters were washed 3610 min in TTBS and incubated with a 1 : 1500 dilution of goat anti-rabbit secondary antibody for 1 h. Filters were washed 6610 min in TTBS and developed by Lumigal chemiluminescence (Pierce) or ECL chemiluminescence (Amersham) according to manufacturer's directions and exposed to Biomax ML ®lm (Kodak).
MEK1/2 in vitro kinase assay
Approximately 10 7 cells were lysed in ice-cold 1 ml lysis buer (10 mM Tris/HCl, pH 7.4, 1% Triton X-100, 5 mM EDTA, 50 mM NaCl, 5 mM NaF, 0.1% BSA, 20 mg/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride, 2 mM Na 3 VO 4 ). Lysates were vortexed and pelleted by centrifugation at 13 500 r.p.m. for 10 min at 48C. Supernatants were incubated with 5 ml of anti-MEK1 or anti-MEK2 monoclonal antibody for 2 h at 48C on an end-over-end rotator. 30 ml of PBS-washed protein-A agarose (Boerhinger Mannheim) was added to the supernatants and the mix was rotated for 1 h at 48C. The immunoprecipitates were washed twice with ice-cold lysis buer and twice with PAN buer (10 mM PIPES, pH 7.0, 100 mM NaCl, 21 mg/ml aprotinin). Immunoprecipitated products were used in kinase assays using the MEK1 assay kit (Upstate Biotechnology, Inc.) according to manufacturer's instructions. Brie¯y, immunoprecipitates were incubated for 30 min at 308C with cold magnesium/ATP cocktail and 1 mg of inactive GST-p42 MAPK in assay dilution buer.
An aliquot of this reaction was then incubated with 20 mg MBP (Gibco BRL Life Technologies), cold ATP and 10 mCi [g-32 P]ATP for 10 min at 308C. Final products were electrophoresed through 15% SDS ± PAGE gels. The gels were dried and exposed to PhosphorImager cassettes for visualization.
MAPK in vitro kinase assays
MAPK assays were performed as previously described (Samuels et al., 1993) . Brie¯y, cells were lysed in ice-cold lysis buer (20 mM Tris, pH 7.9, 137 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 1 mM aprotinin, 1 mM leupeptin, 1 mM pepstatin A, 1 mM Na 3 VO 4 , 1 mM EGTA, 10 mM NaF, 100 mM b-glycerophosphate) and total cell protein was collected by centrifugation at 13 500 r.p.m. to remove insoluble material. Protein concentration was determined with the Bio-Rad Protein Assay kit (Bio-Rad). MAPK proteins were immunoprecipitated from 100 mg total protein with 4 ml of anti-ERK1 or anti-ERK2 polyclonal antibodies, rotating at 48C for 2 h. About 30 ml protein A-agarose was added to each reaction and the mix was rotated for an additional hour at 48C. Products were washed twice in lysis buer and once in 25 mM Tris, pH 7.5, 137 mM NaCl, 40 mM MgCl 2 and 10% glycerol. Immunoprecipitates were then added to a reaction mix containing 40 mM HEPES, pH 7.4, 40 mM MgCl 2 , 200 mM ATP, 5 mCi [g-32 P]ATP and 20 mg MBP. The reaction was allowed to procede for 30 min at 308C. Products were electrophoresed on 15% SDS ± PAGE gels. Gels were dried and exposed to PhosphorImager cassettes.
Nuclear run-os
Nuclei were harvested from 2 ± 5610 7 cells per treatment. Cells were trypsinized and washed with 16phosphate buered saline. Cell pellets were lysed in ice-cold NP-40 lysis buer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.5% NP-40). Lysates were spun for 5 min at 1000 r.p.m. and the nuclei were resuspended at a concentration of 2 ± 5610 7 in 160 ml glycerol buer (50 mM Tris-HCl, pH 8.3, 40% glycerol, 5 mM MgCl 2 , 0.1 mM EDTA) per reaction. Nuclei were labeled in 16run-o buer (0.625 mM ATP, 0.3 mM CTP, 0.3 mM GTP, 3 mM DTT, 1.2 mM MgCl 2 , 80 mM KCl) with 200 mCi [a-32 P]UTP for 30 min at 258C. For the elongation block run-os, 2 ± 5610 7 cells were harvested in solution A (0.3 M sucrose, 60 mM KCl, 15 mM NaCl, 15 mM HEPES, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 0.15 mM spermine, 0.5 mM spermidine, 14 mM b-mercaptoethanol, 0.5% NP-40). Nuclei were resuspended in solution E (50% glycerol, 20 mM Tris-HCl, pH 7.9, 75 mM NaCl, 0.5 mM EDTA 0.85 mM DTT, 0.125 mM PMSF). For the labeling reaction, 2 ± 5610 7 nuclei were resuspended in 36 ml reaction buer (0.3 mM (NH 4 ) 2 SO 4 , 100 mM Tris-HCl pH 7.9, 4 mM MgCl 2 , 4 mM MnCl 2 , 50 mM NaCl, 0.4 mM EDTA, 0.1 mM PMSF, 1.2 mM DTT, 1 mM ATP, 1 mM CTP, 1 mM GTP, 10 mM phosphocreatine, 20 U/ml RNasin), 29 ml glycerol, 200 mCi [a-
32 P]UTP in a total volume of 100 ml. Reactions were allowed to proceed for 15 min at 258C. RNA was harvested by acid guanidinium thiocyanate-phenol-chloroform extraction (Chomczynski and Sacchi, 1987) .
RET probes used for slot blots included a HindIII ± ScaI fragment (`whole' cDNA), an AatII ± KpnI fragment (5' probe), a KpnI ± EcoRI fragment (middle probe), and an EcoRI ± NsiI fragment (3' probe) of the short isoform of the RET cDNA (Ret 9). A ClaI ± HindIII fragment of the luciferase gene from pGL2 (Promega) was used as a negative control. Positive controls included a PstI fragment of GAPDH and a KpnI ± SacI fragment of b 2 -microglobulin. DNA fragments were denatured in 0.4 M NaOH, 2 mM EDTA for 30 min at 378C. The denatured DNAs were transferred to Zeta-Probe. Filters were prehybridized in hybridization solution (0.2% SDS, 10 mM EDTA, 0.5 M NaPhosphate, pH 7.5, 26Denhardt's) at 658C for 5 h. Fresh hybridization solution containing 1 ± 5610 6 counts/ml was added and blots were incubated for 48 h at 658C. Membranes were washed with 26SSC/0.5% SDS for 10 min at 258C, twice, followed by a wash in 0.16SSC.0.5% SDS at 658C for 5 min. Filters were treated with 10 mg/ml RNase A in 26SSC for 30 min at 378C, rinsed with 26SSC, and exposed to a PhosphorImager cassette.
Actinomycin D treatments
TT:D Raf-1:ER cells were cultured as described. Cells were treated with 1 mM b-estradiol or ethanol for 16 h prior to the addition of 5 mg/ml actinomycin D. Cells were harvested at the indicated timepoints. RNA was puri®ed using Trizol reagent (Gibco ± BRL Life Technologies) according to the manufacturer's protocol.
RNase protection assays
Riboprobes were generated corresponding to the EcoRI ± XhoI fragment of Ret and a HincII fragment of human GAPDH. Riboprobes were labeled with the T3/T7 Maxiscript kit (Ambion) according to the manufacturer's protocol. Probes were puri®ed by two rounds of PC-9 extraction followed by EtOH precipitation. The ®nal pellet was resuspended in DEPC-ddH 2 O. RNase protection assays were conducted using the RPAII kit (Ambion), according to manufacturer's instructions. Brie¯y, 10 mg of RNA was dried down and resuspended in hybridization buer. Approximately 1610 6 c.p.m of RET probe and 1610 4 c.p.m. of GAPDH were added to each reaction, denatured, and hybridized 12 ± 16 h at 458C. Hybridized samples were digested with RNase A and electrophoresed through 6% polyacrylamide-urea gels. Gels were dried and exposed to PhosphorImager cassettes.
RNA fractionation
Cells were grown and dierentiated as described. At 0, 24 and 48 h of dierentiation, 10 7 cells were trypsinized, pelleted and resuspended in 16PBS containing 0.5 mM EDTA. Cells were pelleted at 2000 r.p.m. for 5 min. Cell pellets were resuspended in 250 ml TE (10 mM Tris-HCl, pH 7.6, 1 mM EDTA) and 12 ml 10% NP-40. Cells were mixed and placed on ice for 5 min. A second 12 ml of 10% NP-40 was added and the cells were incubated on ice, 5 min. Lysates were spun for 3 min at 8000 r.p.m., 48C. RNA was extracted from the pelleted nuclei by acid guanidinium thiocyanate-phenol-chloroform extraction (Chomczynski and Sacchi, 1987) . Cytoplasmic RNA was extracted from the supernatant by adding an equivalent volume of a 2 : 1 mix of water-saturated phenol:(200 mM Tris, 100 mM NaCl, 20 mM EDTA, 2% SDS). The mixture was vortexed and spun at 13 500 r.p.m., 5 min at 48C. The aqueous layer was extracted with phenol:CHCl 3 :isoamyl alcohol (25 : 24 : 1), and centrifuged 5 min at 13 500 r.p.m., 48C. The resulting aqueous phase was extracted with an equal volume CHCl 3 :isoamyl alcohol. The ®nal aqueous phase was precipitated with two volumes of absolute EtOH to recover the RNA. RNA pellets were dissolved in DEPCddH 2 O.
RET Constructs and Infections
The short isoform of RET (RET 9) was used for these experiments. EcoRV ± ScaI fragments of pRETSF2A and pRETSF2B (encompassing the entire coding domain) were isolated, blunt ended with Klenow polymerase, and ligated into the SnaBI site of pBabehygro (Morgenstern and Land, 1990). Directionality was assured by BglII digestion. Constructs were transfected into PA317 cells with Lipofectamine (Gibco ± BRL Life Technologies), according to manufacturer's directions. PA317 cells were selected for 10 days in 0.1 mg/ml hygromycin and individual clones were picked and expanded. PA317 clones were checked for RET expression and titered for virus production. PA317 lines were used to infect NIH3T3 cells, PC12 cells, and TT:DRaf-1:ER cells. Selective media was replaced with hygromycin-free media 24 h before viral supernatants were harvested. PA317 supernatants were ®ltered through a 0.2 mm ®lter and applied to approximately 0.5 ± 1610 6 recipient cells per well of a 6 well plate in the presence of 2 mg/ml polybrene for 48 h NIH3T3 cells were stained for foci in about 3 weeks. PC12 cells were split 1 : 10 and selected in 0.1 mg/ml hygromycin. TT:DRaf-1:ER cells were split 1 : 5 and selected in the presence of 0.4 mg/ml hygromycin. Pooled populations and individual clones of TT:DRaf-1:ER RET cells were picked and maintained independently.
Immunoprecipitations
Cells were grown in T-25¯asks and dierentiated when 70 ± 80% con¯uent. Cells were harvested in 1 ml ice-cold RIPA buer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris, pH 7.5) containing 5 mg/ml aprotinin, 1 mg/ml leupeptin, 0.1 mg/ml PMSF and 1 mM Na 3 VO 4 . Lysates were vortexed and pelleted for 10 min at 13 500 r.p.m. at 48C. Lysates were precleared with 30 ml of PBSwashed protein A-agarose, rotating at 48C, 1 h. Supernatants were transferred to clean tubes and 4 ml of an anti-RET polyclonal antibody raised to the C-terminus of RET (Santa Cruz Biotechnology, was added. The lysates were rotated 1 ± 2 h at 48C. Thirty ml PBS-washed protein Aagarose were added and the tubes were rotated another hour at 48C. Samples were washed ®ve times in RIPA buer. The ®nal immunoprecipitates were resuspended in 35 ml 26Laemmli buer and electrophoresed through 7% SDS ± PAGE gels. Gels were transferred to nitrocellulose (Bio-Rad) and developed as described above, using a 1 : 1000 dilution of 4G10 anti-phosphotyrosine antibody and a 1 : 2000 dilution of goat anti-mouse secondary antibody. Blots were stripped according to Amersham ECL protocol and redeveloped with a 1 : 1000 dilution of anti-RET immunoprecipitating antibody and a 1 : 1500 dilution of goat anti-rabbit secondary antibody to control for the amount of RET protein on the ®lter.
RT ± PCR analyses
Cells were grown and dierentiated and RNA was harvested using the Trizol reagent according to manufacturer's protocol. Reverse transcriptase reactions were conducted RT buer (50 mM Tris-HCl, pH 7.5, 75 mM KCl, 10 mM DTT, 3 mM MgCl 2 , 2 mM each dNTP, 0.5 U/ ml RNasin), with 200 U MMLV-reverse transcriptase 200 ng random hexamers per 1 mg RNA. RT minus controls were included for each reaction. Reactions were incubated at 378C for 1 h. Products were extracted with PC-9 and ethanol precipitated. Primer used for PCR included RET2A.1 (5'-TCAGGACTGCCTCCG GGGC-AG-3'), RET2A.2 (5'-GGGCCTCCGGAAGGTCATCTC-3'), RET-RSA (5'-GCCAGG GTCGGATTCCAGTTA-AATGTA-3'), and RET6 (5'-TGTCTGGCCTCTCCATC-CGGT-3'). RET2A PCR reactions were conducted in 20 mM Tris-HCl (pH 7.9), 1.5 mM MgC 2 , 50 mM KCl, 0.1 mg/ ml BSA, 200 mM each dNTP, 100 ng RET2A.1, 100 ng RET2A.2, with one-third of the RT product and 1 unit Taq polymerase (Gibco ± BRL Life Technologies) per reaction. Reactions were cycled at 958C, 30 s, 658C, 30 s for 35 cycles. RET2B PCR reactions were conducted in 20 mM Tris-HCl (pH 7.9), 2.0 mM MgCl 2 , 50 mM KCl, 0.1 mg/ml BSA, 200 mM each dNTP, 100 ng RET ± RSA, 100 ng RET6, with one-third of the RT product and 1 unit Taq polymerase per reaction. Reactions were cycled at 958C, 30 s, 638C, 30 s, 728C, 30 s for 35 cycles. PCR products were checked by agarose gel electrophoresis for DNA contamination in the RT minus lanes. PCR products were then PC-9 extracted and ethanol precipitated. To compare the endogenous and exogenous products, RET2A products were digested with TseI, which selectively cut the exogenous RET. RET2B products were digested with RsaI, which selectively cut the exogenous RET due to the creation of an RsaI site due to a mismatch in the primer juxtaposed with the 2B mutation (Marsh et al., 1996) . Digested PCR products were electrophoresed through 6% PAGE gels and stained with EtBr to visualize the products.
Northern blots
Northern blot protocols and probes for CT, CGRP and GAPDH have been described previously (Carson et al., 1995) . Blots were quantitated by PhosphorImager and ImageQuant analysis.
